Taken together, above data indicate that the patients bearing a tumor with wild type TP53 experience bad prognosis, and this associates with high expression of BECN1 and BRCA1 mRNA and with platinum-resistance, while the opposite is observed for the patients bearing a tumor with mutated TP53 that associated with decreased mRNA levels of BECN1 and BRCA1 (Figure 1). Here, BECN1 is linked to neoplasm.